stockportfolio.pro
Stocks / ALKS vs TGTX
ALKS vs TGTX
Alkermes plc and TG Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Alkermes plc (ALKS) | TG Therapeutics, Inc. (TGTX) | |
|---|---|---|
| Market cap | $7.3B | $7.1B |
| Revenue (latest FY) | $1.48B | $616.29M |
| Net income (latest FY) | $241.66M | $447.18M |
| Revenue growth (5y CAGR) | 7.3% | 426.7% |
| Net margin | 16.4% | 72.6% |
| Return on equity | 13.3% | 69.0% |
| P/E ratio | 49.0 | 16.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 3 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ALKS — free Open TGTX — freeFrequently asked questions
Which is bigger, ALKS or TGTX?
Alkermes plc is larger by market capitalization — $7.3B versus $7.1B.
Which grows faster, ALKS or TGTX?
Over the last five fiscal years, TG Therapeutics, Inc. grew revenue faster — 426.7%/yr versus 7.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.